Although the mutational landscape of BIA-ALCL is not fully elucidated, activating somatic mutations have been described in STAT3, STAT5B, JAK1 and JAK2 and loss of function mutations in SOCS1 and SOCS3 pointing to the importance of activation of the JAK/STAT pathway also in this disease. This evidence concerns the gene STAT3 and anaplastic large cell lymphoma.